Skip to main content
Erschienen in: Reproductive Biology and Endocrinology 1/2015

Open Access 01.12.2015 | Research

No association between polymorphisms in PTEN and primary ovarian insufficiency in a Han Chinese population

verfasst von: Weiwei Zou, Binbin Wang, Jing Wang, Zhiguo Zhang, Xiaofeng Xu, Beili Chen, Xu Ma, Yunxia Cao

Erschienen in: Reproductive Biology and Endocrinology | Ausgabe 1/2015

Abstract

Background

The aim of our study was to investigate the possible relationship between polymorphisms in PTEN (the phosphatase and tensin homolog located on chromosome ten in humans) and POI (primary ovarian insufficiency) in Chinese women.

Methods

Seven tag SNPs (single nucleotide polymorphisms) - rs1234219, rs1903858, rs2299939, rs35352882, rs17107001, rs2299941 and rs12572106 - were chosen from the CHB (Han Chinese people in Beijing, China) HapMap database. MALDI-TOF-MS (matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry) was used to detect the genotype distribution of the seven SNPs among 148 POI patients and 230 controls.

Results

No statistically significant difference was found in an association analysis of the seven SNPs in the allele frequencies, genotype frequencies, or haplotype distributions.

Conclusions

In summary, this study explored the relationship between polymorphisms in PTEN and POI in a Han Chinese population and suggests that polymorphisms in PTEN may not be associated with a risk of POI.
Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

WZ completed the molecular genetic studies and drafted the manuscript. BW participated in the design of the study and performed the statistical analysis. JW performed the statistical analysis. ZZ, XX and BC participated in the acquisition of samples. XM participated in the design of the study and helped to draft the manuscript. YC conceived of the study, participated in its design and helped to draft the manuscript. All of the authors read and approved the final manuscript.
Abkürzungen
CHB
(Han Chinese people in Beijing, China)
CI
(confidence interval)
DSB
(DNA double-strand break)
ES
(Embryonic stem)
HWE
(Hardy-Weinberg equilibrium)
LD
(Linkage disequilibrium)
MALDI-TOF-MS
(Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry)
OR
(Odds ratio)
PI3K
(Phosphoinositide-3 kinase)
POI
(primary ovarian insufficiency)
PTEN
(the phosphatase and tensin homolog located on chromosome ten in humans)
PTEN
(The protein encoded by the phosphatase and tensin homolog located on chromosome ten in humans)
SNP
(Single nucleotide polymorphism)

Background

POI (primary ovarian insufficiency) is characterised by reduced ovarian function in women under 40 years of age. It results from a decrease in the number of ovarian follicles, follicle exhaustion or follicle insensitivity to gonadotropins [1]. It has been reported that approximately 1 % of women under 40 years of age with a normal karyotype are affected by this disease [2]. In the vast majority of POI patients, its aetiology is unknown [3], but it is thought to have a genetic basis [2].
In mammals, the initial number of primordial follicles in the ovary is fixed early in life. Before puberty begins, partial primordial follicles in dormancy are activated and develop to the antral follicle stage. At the onset of puberty, antral follicles either develop into mature follicles or become apoptotic. The remaining primordial follicles remain in a dormant state and wait for further development or undergo apoptosis directly from dormancy [4]. The gradual and natural reduction and ultimate depletion in the number of primordial follicles leads to a gradual deterioration of the ovary, after which the female enters menopause [4]. How can primordial follicles maintain such a long dormant state during a female’s entire reproductive life? Previous studies have found that some signal molecules, such as PTEN (the protein encoded by the phosphatase and tensin homolog located on chromosome ten in humans), are relevant to this process [5]. Deletion of Pten in mouse oocytes results in the premature activation and eventually exhaustion of the global primordial follicles in early adulthood and thus leads to premature ovarian insufficiency [5].
PTEN is a tumour suppressor that has dual-phosphatase activity. Down-regulation of its expression or dysfunction of the PTEN (the phosphatase and tensin homolog located on chromosome ten in humans) is closely related to the occurrence of numerous human tumours [6]. PTEN can influence cell apoptosis, invasion and angiogenesis through its down-regulation of the PI3K (phosphoinositide-3 kinase) signal pathway, and it can therefore inhibit the survival and invasion of tumour cells [6]. PTEN also plays an important role in stabilising chromosomes and participates in controlling DSB (DNA double-strand break) repair [7].
Mutations of Pten in ES (embryonic stem) cells have a negative influence on early embryonic differentiation in mice and lead to early embryonic death [8]. This suggests that Pten is essential for the development of mouse embryos [8]. Pten-knockout mice consistently exhibit higher levels of FSH and LH, reduced ovarian function and female infertility [5]. Scientists have also cultured ovaries from newborn mice in vitro in the presence of a PTEN inhibitor and PI3K activator and found that primordial follicles were activated from dormancy [9]. They subsequently cultured human ovarian cortical fragments with the PTEN inhibitor; primordial follicles were activated and demonstrated the ability to develop into mature follicles [9].
Given the above findings, we suspected that functional deficiency or dysfunction of PTEN in humans might result in damaged ovarian functions and lead to primary ovarian insufficiency. We therefore explored a possible relationship between polymorphisms of PTEN and POI in Chinese women.

Methods

This study was approved by the institutional ethical committee of Anhui Medical University. All participants were informed of and consented to the experiment.

Subjects

In total, 378 Chinese women, including 148 POI patients (mean age ± SD, 29.7 ± 6.1 years) (E2 96.1 ± 82.1 pmol/L, FSH 74.1 ± 30.6 mIU/mL, LH 37.6 ± 19.3 mIU/mL) and 230 controls (mean age ± SD, 30.2 ± 3.7 years) (E2 187.3 ± 92.5 pmol/L, FSH 6.5 ± 1.6 mIU/mL, LH 5.3 ± 3.1 mIU/mL), were recruited from the First Affiliated Hospital, Anhui Medical University, China. We chose POI patients who had had amenorrhea for more than 6 months and had normal diploid karyotypes and serum FSH levels > 30 IU/L [10]. We excluded patients who had undergone pelvic surgery, had been diagnosed with an autoimmune disease, or had ever received chemotherapy or radiotherapy. All of the controls were healthy Chinese women with natural menstrual cycles, normal FSH values and no evidence of diseases affecting normal ovarian function (including large ovarian or ovarian endometriosis cysts, severe tubal lesions, hypothalamus or pituitary tumours, obesity, abnormal adrenal function, thyroid disease, etc.). The approval and consent of the institutional ethics committee of Anhui Medical University was obtained for this experiment.
Considering the pathogenic mechanism of PTEN, the POI patients were divided into several groups: those with primary amenorrhea and secondary amenorrhea and early amenorrhea (including 22 primary amenorrhea patients and 4 patients with amenorrhea that only experienced menarche, but developed amenorrhea immediately after the initial menses) and late amenorrhea (secondary amenorrhea, excluding 4 patients with amenorrhea that only experienced menarche, but developed amenorrhea immediately after the initial menses).

Methods and genetic analysis

A QIAamp DNA Blood Mini Kit (Qiagen, Germany) was used for genomic DNA purification from peripheral blood. Seven tag SNPs - rs1234219, rs1903858, rs2299939, rs35352882, rs17107001, rs2299941 and rs12572106 - were chosen from the CHB (Han Chinese people in Beijing, China) HapMap database [11]. The criteria for selection were tag SNPs with a MAF (minor allele frequency) > 0.05 and r2 > 0.8. MALDI-TOF-MS (matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry) (Illumina, US) was used to detect the genotypes of the seven SNPs in the extracted samples from the POI patients and controls. To control the quality, we performed the detections repeatedly in both standard samples and experimental samples.

Statistical analysis

Comparative analyses of the allele frequencies and genotype frequencies of rs1234219, rs1903858, rs2299939, rs35352882, rs17107001, rs2299941 and rs12572106 between POI patients and controls were performed with Pearson’s chi-squared tests using SPSS 13.0 software. We used Fisher’s exact test if the expected count was less than 5 in any of the cells. Odds ratios (ORs) and their matching 95 % confidence intervals (CIs) were computed using logistic regression analysis via SPSS 13.0 software. The HWE (Hardy-Weinberg equilibrium) of each SNP polymorphism in POI patients and controls was evaluated using Pearson’s chi-squared tests, and we also applied Fisher’s exact test if the expected count was less than 5 in any of the cells. LD (Linkage disequilibrium), haplotype association analysis and permutation tests were performed using HaploView 4.2 software. Haplotypes with frequencies less than 0.05 were excluded. To avoid statistical errors, we performed multiple comparisons using Bonferroni correction. Data with p-values < 0.05 were considered statistically significant.

Results

The LD plot of the seven SNPs (single nucleotide polymorphisms) in the PTEN region is shown in Fig. 1. Only two SNPs (rs12572106 and rs2299941) were in strong LD. The seven SNPs are located in the introns of PTEN.
The allele frequencies and association analysis of the seven SNPs are shown in Table 1. In both POI patients and controls, the seven SNPs of PTEN were all in an HWE state. The allele frequencies of rs2299939 showed a statistically significant difference (p <0.05) between POI patients and controls. However, after Bonferroni correction, no significant difference was found for any of the SNPs.
Table 1
The allele frequencies of the seven SNPs in PTEN between POI patients and controls
SNP
Alleles
Associated allele
HWE cases
HWE controls
MAF cases (n = 148)
MAF controls (n = 230)
OR
95 % CI
Value
p
Bonferroni correction
rs1234219
T/C
C
0.95
0.72
0.084
0.084
1.010
0.596–1.711
0.001
0.971
1.000
rs1903858
C/T
C
0.60
0.90
0.446
0.509
0.777
0.579–1.043
2.834
0.092
0.644
rs2299939
C/A
C
0.45
0.16
0.146
0.206
0.661
0.445–0.982
4.230
0.040
0.280
rs35352882
T/C
C
0.58
0.51
0.044
0.042
1.047
0.509–2.153
0.015
0.901
1.000
rs17107001
G/T
T
0.64
0.63
0.037
0.031
1.208
0.541–2.697
0.212
0.645
1.000
rs2299941
A/G
G
0.68
0.62
0.378
0.354
1.111
0.820–1.505
0.460
0.498
1.000
rs12572106
T/C
C
0.74
0.44
0.443
0.389
1.245
0.925–1.676
2.091
0.148
1.000
The allele frequencies were performed with Pearson’s chi-squared test or Fisher’s exact test using SPSS 13.0 software. The allele frequencies of rs2299939 showed no significant difference after Bonferroni correction between POI patients and the controls
The genotype frequencies of the seven SNPs are shown in Table 2. There was no statistically significant difference for any of the SNPs between POI patients and controls in genotype frequencies.
Table 2
The genotype frequencies of the seven SNPs in PTEN between POI patients and controls
SNP
Genotypes, n
Value
p
OR (95 % CI)
rs1234219
T/T
T/C
C/C
Missing
   
Cases
124
23
1
0
0.201
0.950
0.770 (0.069–8.584)
Controls
191
34
2
3
  
1.042 (0.586–1.852)
rs1903858
C/C
C/T
T/T
Missing
   
Cases
47
70
31
0
2.889
0.236
1.367 (0.837–2.233)
Controls
55
112
59
4
  
0.841 (0.496–1.425)
rs2299939
C/C
C/A
A/A
Missing
   
Cases
106
39
2
1
5.319
0.070
4.719 (1.043–21.353)
Controls
146
67
13
4
  
3.784 (0.811–17.651)
rs35352882
T/T
T/C
C/C
Missing
   
Cases
135
13
0
0
0.016
0.899
1.049 (0.502–2.195)
Controls
207
19
0
4
   
rs17107001
G/G
G/T
T/T
Missing
   
Cases
137
11
0
0
0.220
0.639
0.822 (0.363–1.864)
Controls
212
14
0
4
   
rs2299941
A/A
A/G
G/G
Missing
   
Cases
56
72
20
0
0.854
0.652
1.080 (0.568–2.052)
Controls
96
100
30
4
  
0.875 (0.455–1.684)
rs12572106
T/T/
T/C
C/C
Missing
   
Cases
47
71
30
0
2.048
0.359
1.501 (0.825–2.730)
Controls
87
102
37
4
  
1.288 (0.808–2.054)
The genotype frequencies were performed with Pearson’s chi-squared test or Fisher’s exact test using SPSS 13.0 software. There was no significant difference between POI patients and the controls
The haplotype distributions of five SNPs are shown in Table 3. Only two genotypes were found for two SNPs (rs35352882 and rs17107001), and the MAF was under 0.05. Because the inclusion of those two SNPs could result in a considerable statistical error, we analysed only the other five SNPs for haplotype distributions. The p-value of T-T-A-A-T showed a statistically significant difference (p < 0.05), but there was no significant difference after 104 permutation tests.
Table 3
The haplotype distributions of PTEN polymorphisms in POI patients and controls
Haplotype
Total frequency
Cases frequency
Controls frequency
p-value
p-value from permutation
T-C-C-G-C
0.358
0.378
0.345
0.355
0.820
T-T-C-A-T
0.302
0.301
0.302
0.959
1.000
T-T-A-A-T
0.181
0.145
0.204
0.042
0.175
C-C-C-A-T
0.084
0.084
0.084
0.971
1.000
The haplotype association analysis was performed using the HaploView 4.2 software. The p-value of T-T-A-A-T showed a statistically significant difference, but there was no significant difference after 104 permutation tests
There was no statistically significant difference in the allelic and genotypic distributions between primary and secondary amenorrhea, early and late amenorrhea and the control groups after Bonferroni correction (Table 4, Table 5).
Table 4
The association analysis of the seven SNPs among the primary amenorrhea, secondary amenorrhea and control groups
SNP
Genotypes, n
Value
p
Alleles
Value
P
Bonferroni correction
rs1234219
T/T
T/C
C/C
Missing
  
T
C
   
Primary amenorrhea
19
3
0
0
0.659
0.989
41
3
0.093
0.976
1.000
Secondary amenorrhea
105
20
1
0
  
230
22
   
Controls
191
34
2
3
  
416
38
   
rs1903858
C/C
C/T
T/T
Missing
  
C
T
   
Primary amenorrhea
3
14
5
0
7.452
0.114
20
24
4.883
0.087
0.609
Secondary amenorrhea
44
56
26
0
  
144
108
   
Controls
55
112
59
4
  
222
230
   
rs2299939
C/C
C/A
A/A
Missing
  
C
A
   
Primary amenorrhea
19
3
0
0
6.694
0.132
41
3
6.346
0.042
0.294
Secondary amenorrhea
87
36
2
1
  
210
40
   
Controls
146
67
13
4
  
359
93
   
rs35352882
T/T
T/C
C/C
Missing
  
T
C
   
Primary amenorrhea
20
2
0
0
0.179
1.000
42
2
0.180
0.956
1.000
Secondary amenorrhea
115
11
0
0
  
241
11
   
Controls
207
19
0
4
  
433
19
   
rs17107001
G/G
G/T
T/T
Missing
  
G
T
   
Primary amenorrhea
21
1
0
0
0.478
0.832
43
1
0.451
0.835
1.000
Secondary amenorrhea
116
10
0
0
  
242
10
   
Controls
212
14
0
4
  
438
14
   
rs2299941
A/A
A/G
G/G
Missing
  
A
G
   
Primary amenorrhea
9
11
2
0
1.205
0.886
29
15
0.774
0.679
1.000
Secondary amenorrhea
47
61
18
0
  
155
97
   
Controls
96
100
30
4
  
292
160
   
rs12572106
T/T
T/C
C/C
Missing
  
T
C
   
Primary amenorrhea
7
13
2
0
4.244
0.370
27
17
2.766
0.251
1.000
Secondary amenorrhea
40
58
28
0
  
138
114
   
Controls
87
102
37
4
  
276
176
   
The allele and genotype frequencies among the primary amenorrhea, secondary amenorrhea and control groups were performed with Pearson’s chi-squared test or Fisher’s exact test using SPSS 13.0 software. There was no statistically significant difference in the allelic and genotypic distributions between the primary amenorrhea, secondary amenorrhea and control groups after Bonferroni correction
Table 5
The association analysis of the seven SNPs among the early amenorrhea, late amenorrhea and control groups
SNP
Genotype, n (%)
Value
p
Alleles
Value
P
Bonferroni correction
rs1234219
T/T
T/C
C/C
Missing
 
0.945
T
C
 
0.810
1.000
Early amenorrhea
23
3
0
0
0.820
49
3
0.418
Late amenorrhea
101
20
1
0
 
222
22
 
Controls
191
34
2
3
 
416
38
 
rs1903858
C/C
C/T
T/T
Missing
 
0.195
C
T
 
0.168
1.000
Early amenorrhea
5
16
5
0
6.057
26
26
3.572
Late amenorrhea
42
54
26
0
 
138
106
 
Controls
55
112
59
4
 
222
230
 
rs2299939
C/C
C/A
A/A
Missing
 
0.143
C
A
 
0.044
0.308
Early amenorrhea
22
4
0
0
6.515
48
4
6.267
Late amenorrhea
84
35
2
1
 
203
39
 
Controls
146
67
13
4
 
359
93
 
rs35352882
T/T
T/C
C/C
Missing
 
0.955
T
C
 
0.957
1.000
Early amenorrhea
24
2
0
0
0.101
50
2
0.095
Late amenorrhea
111
11
0
0
 
233
11
 
Controls
207
19
0
4
 
433
19
 
rs17107001
G/G
G/T
T/T
Missing
 
0.704
G
T
 
0.711
1.000
Early amenorrhea
25
1
0
0
0.679
51
1
0.840
Late amenorrhea
112
10
0
0
 
234
10
 
Controls
212
14
0
4
 
438
14
 
rs2299941
A/A
A/G
G/G
Missing
 
0.731
A
G
 
0.776
1.000
Early amenorrhea
9
15
2
0
2.056
33
19
0.506
Late amenorrhea
47
57
18
0
 
151
93
 
Controls
96
100
30
4
 
292
160
 
rs12572106
T/T
T/C
C/C
Missing
 
0.527
T
C
 
0.352
1.000
Early amenorrhea
7
15
4
0
3.189
29
23
2.091
Late amenorrhea
40
56
26
0
 
136
108
 
Controls
87
102
37
4
 
276
176
 
The allele and genotype frequencies among the early amenorrhea, late amenorrhea and control groups were performed with Pearson’s chi-squared test or Fisher’s exact test using SPSS 13.0 software. There was no statistically significant difference in the allelic and genotypic distributions between the early amenorrhea, late amenorrhea and control groups after Bonferroni correction

Discussion

There are two mechanisms that are involved in the occurrence of POI: follicle dysfunction and follicle premature exhaustion [3]. Follicle premature exhaustion indicates the accelerated apoptosis of primordial follicles or premature activation of primordial follicles. Therefore, the survival of primordial follicles is necessary for normal ovarian function. Early researchers inferred that there are inhibitory factors in intact ovarian tissue that maintain the majority of primordial follicles in a dormant state [12]. Previous studies have demonstrated that the PI3K signal pathway is one of the crucial molecular mechanisms that are involved in the survival, dormancy and apoptosis of mammalian primordial follicles [13]. Multiple signal molecules of this pathway were recognised as either stimulating factors (such as Ribosomal protein S6) or inhibitory factors (such as tuberous sclerosis complex 1 and tuberous sclerosis complex 2) in maintaining the balance of the activation and dormancy of mammalian primordial follicles [13, 14]. PTEN down-regulates the PI3K signal pathway [13]. The functional deficiency or dysfunction of Pten leads to continuous and excessive activation of the downstream signal pathway and results in excessive activation and depletion of primordial follicles, ultimately leading to ovarian failure in mice [13, 14]. Before the complete depletion of primordial follicles, Pten mutant mice undergo normal ovulation and generate normal offspring [15, 16].
In the present study, we sought to study the relationship between seven SNPs (rs1234219, rs1903858, rs2299939, rs35352882, rs17107001, rs2299941 and rs12572106) in PTEN and POI in 148 POI patients and 230 controls. We performed an association analysis of the seven SNPs with regard to their allele frequencies, genotype frequencies and haplotype distributions. Rs2299939 showed a statistically significant difference in allele frequency, but the difference disappeared after Bonferroni correction. Haplotype T-T-A-A-T showed an association with POI, but it too disappeared after 104 permutation tests.
POI is a complex disease that involves multiple genes. Although many genes have been confirmed as being involved in the development of POI [2], the cause of most cases remains unidentified. Therefore, many investigators have devoted their research to identifying the aetiology of POI. Because previous studies have found that the deletion of PTEN in oocytes leads to the failure of ovarian function in mice [5], we sought to determine whether PTEN is involved in the incidence and development of human POI. We did not find an association between POI and any risk alleles, genotypes or haplotypes. There are several possible explanations for these results. First, PTEN has never been demonstrated to be associated with human POI. In addition, specific differences between mice and humans may account for genetic differences in the PTEN region. Although researchers have found that compared to mice more primordial follicles were activated in human ovarian cortical fragments after treatment with a PTEN inhibitor [9], they did not analyse the statistical significance of the difference. In addition, that study’s sample size may not have been sufficiently large. In the previous study, the increased gonadotropin concentrations, morphological changes of the ovary and the depletion of primordial follicles began to appear 12 weeks postnatal in PTEN mutant mice. In humans, the period from birth to puberty may last over 10 years. If the gene mutation or abnormal function of PTEN occurs in the embryonic or early life, it is likely that ovarian primordial follicles may be activated and exhausted before puberty, which may present as primary amenorrhea. If the gene mutation or abnormal function of PTEN occurs after puberty, it behaves as secondary amenorrhea. Therefore, we divided the cases into primary and secondary amenorrhea and early and late amenorrhea and compared the patients with the controls. If we obtained meaningful results, we could affirm the association between PTEN and POI and could also infer the approximate time of the PTEN mutation. Rs2299939 showed a statistically significant difference between these groups in allele frequency, but the difference disappeared after Bonferroni correction. The primary amenorrhea sample size was too small. A larger sample size of primary amenorrhea POI patients may yield statistically significant results, especially considering the promising rs2299939 allele and T-T-A-A-T haplotype.
Researchers analysed the PCR products of the PTEN encoding region via direct sequencing in 20 idiopathic POI patients and 20 controls, but found no meaningful mutation [17]. We hypothesise that a larger sample size may improve results, and in population genetics, many different results are due to the varied composition of the studied populations. Chinese scientists had already performed a mutation analysis of nine exons of PTEN in 161 Chinese women with POI but did not observe any mutations or variants [18]. The sample size of their study was similar to the sample size used in the present study, and they researched PTEN from various angles, performing mutational analysis of exons and conducting an association study of intronic SNPs. The two studies mutually remedy their respective defects and together indicate that PTEN may not participate in the pathogenesis of POI. In addition, the POI patients in the two studies were all secondary amenorrhea patients. Thus, we need to confirm the results in a larger sample of patients with primary amenorrhea.

Conclusions

In summary, this study investigated the relationship between polymorphisms of PTEN and POI in a Chinese Han population. Our findings suggest that PTEN may not be a common pathogenic gene for POI in humans. However, further studies in a larger sample size or functional studies of PTEN are needed to verify these results.

Acknowledgments

The authors thank all of the women who participated in this study and all of the clinicians who collected these cases. We thank Yunxia Cao, who provided medical writing services on behalf of the State Key Development Program for Basic Research of China (2012CB944704) and the National Natural Science Foundation of China (30973197). We thank the English language professional service (http://​webshop.​elsevier.​com/​languageediting/​) for correcting the spelling and grammar errors. This study was supported by the State Key Development Program for Basic Research of China (2012CB944704) and the National Natural Science Foundation of China (30973197).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

WZ completed the molecular genetic studies and drafted the manuscript. BW participated in the design of the study and performed the statistical analysis. JW performed the statistical analysis. ZZ, XX and BC participated in the acquisition of samples. XM participated in the design of the study and helped to draft the manuscript. YC conceived of the study, participated in its design and helped to draft the manuscript. All of the authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68:499–509.CrossRef Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68:499–509.CrossRef
2.
Zurück zum Zitat Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet. 2011;283:635–43.PubMedCrossRef Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet. 2011;283:635–43.PubMedCrossRef
3.
Zurück zum Zitat Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2011;360:606–14.CrossRef Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2011;360:606–14.CrossRef
4.
Zurück zum Zitat McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21:200–14.PubMed McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21:200–14.PubMed
5.
Zurück zum Zitat Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2000;319:611–3.CrossRef Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2000;319:611–3.CrossRef
6.
7.
Zurück zum Zitat Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–70.PubMedCrossRef Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–70.PubMedCrossRef
8.
Zurück zum Zitat Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 2007;19:348–55. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 2007;19:348–55.
9.
Zurück zum Zitat Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A. 2010;107:10280–4.PubMedCentralPubMedCrossRef Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A. 2010;107:10280–4.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Wandji SA, Srsen V, Voss AK, Eppig JJ, Fortune JE. Initiation in vitro of growth of bovine primordial follicles. Biol Reprod. 1996;55:942–8.PubMedCrossRef Wandji SA, Srsen V, Voss AK, Eppig JJ, Fortune JE. Initiation in vitro of growth of bovine primordial follicles. Biol Reprod. 1996;55:942–8.PubMedCrossRef
13.
Zurück zum Zitat Reddy P, Zheng W, Liu K. Mechanisms maintaining the dormancy and survival of mammalian primordial follicles. Trends Endocrinol Metab. 2010;21:96–103.PubMedCrossRef Reddy P, Zheng W, Liu K. Mechanisms maintaining the dormancy and survival of mammalian primordial follicles. Trends Endocrinol Metab. 2010;21:96–103.PubMedCrossRef
14.
Zurück zum Zitat Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev. 2009;30:438–64.PubMedCrossRef Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev. 2009;30:438–64.PubMedCrossRef
15.
Zurück zum Zitat John GB, Gallardo TD, Shirley LJ, Castrillon DH. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev Biol. 2008;321:197–204.PubMedCentralPubMedCrossRef John GB, Gallardo TD, Shirley LJ, Castrillon DH. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev Biol. 2008;321:197–204.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Jagarlamudi K, Liu L, Adhikari D, Reddy P, Idahl A, Ottander U, et al. Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One. 2009;4:e6186.PubMedCentralPubMedCrossRef Jagarlamudi K, Liu L, Adhikari D, Reddy P, Idahl A, Ottander U, et al. Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One. 2009;4:e6186.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Shimizu Y, Kimura F, Takebayashi K, Fujiwara M, Takakura K, Takahashi K. Mutational analysis of the PTEN gene in women with premature ovarian failure. Acta Obstet Gynecol Scand. 2009;88:824–5.PubMedCrossRef Shimizu Y, Kimura F, Takebayashi K, Fujiwara M, Takakura K, Takahashi K. Mutational analysis of the PTEN gene in women with premature ovarian failure. Acta Obstet Gynecol Scand. 2009;88:824–5.PubMedCrossRef
18.
Zurück zum Zitat Zhao Z, Qin Y, Ma J, Zhao H, Li J, Wang L, et al. PTEN gene analysis in premature ovarian failure patients. Acta Obstet Gynecol Scand. 2011;90:678–9.PubMedCrossRef Zhao Z, Qin Y, Ma J, Zhao H, Li J, Wang L, et al. PTEN gene analysis in premature ovarian failure patients. Acta Obstet Gynecol Scand. 2011;90:678–9.PubMedCrossRef
Metadaten
Titel
No association between polymorphisms in PTEN and primary ovarian insufficiency in a Han Chinese population
verfasst von
Weiwei Zou
Binbin Wang
Jing Wang
Zhiguo Zhang
Xiaofeng Xu
Beili Chen
Xu Ma
Yunxia Cao
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Reproductive Biology and Endocrinology / Ausgabe 1/2015
Elektronische ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-015-0057-5

Weitere Artikel der Ausgabe 1/2015

Reproductive Biology and Endocrinology 1/2015 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.